Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 16;21(1):6.
doi: 10.1186/s12962-023-00417-z.

Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain

Dolores Isla  1 , Marta Lopez-Brea  2 , María Espinosa  3 , Natalia Arrabal  4 , Diego Pérez-Parente  4 , David Carcedo  5 , Reyes Bernabé-Caro  6   7
Affiliations

Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain

Dolores Isla et al. Cost Eff Resour Alloc. .

Abstract

Background: Atezolizumab has recently been approved for first-line treatment of high PD-L1 expression metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with no EGFR or ALK mutations, on the basis of the IMpower110 trial. This study aims to estimate the cost-effectiveness of atezolizumab compared with pembrolizumab among these patients in Spanish settings, based on the results of the two cut-offs of the IMpower110 study.

Methods: A three-state partitioned-survival model was adapted to Spanish settings to calculate health outcomes and costs over a lifetime horizon. Clinical data for atezolizumab were collected from the interim and the exploratory results (data cut-off: Sept'18 and Feb'20, respectively) of the IMpower110 trial while a network meta-analysis was used to model pembrolizumab treatment. Utility data were collected from the trial. Direct medical costs were considered based on resources identified by experts. Costs and outcomes were discounted at 3% per year. Health outcomes were expressed as cost per Life Year (LY) and cost per Quality-Adjusted Life Year (QALY). Both deterministic and probabilistic sensitivity analyses were performed to assess the robustness of results.

Results: Over a lifetime horizon, the incremental results showed that atezolizumab generated similar health outcomes (LYs and QALYs) to pembrolizumab, with minimal differences depending on the cut-off used (+ 0.70 and + 0.42 LYs and QALYs with Sept'18 cut-off and - 0.80 and - 0.72 LYs and QALYs with Feb'20 cut-off). However, for both cut-offs, atezolizumab produced meaningfully less costs than pembrolizumab (€ - 54,261 with Sept'18 cut-off and € - 81,907 with Feb'20 cut-off). The sensitivity analyses carried out confirmed the robustness of the base-case results.

Conclusions: The cost-effectiveness analysis, comparing the two cut-off of IMpower110, shows that atezolizumab provides similar health gains to pembrolizumab but at a lower cost for the first-line treatment of metastasic NSCLC patients in Spain.

Keywords: Atezolizumab; Cost-effectiveness analysis; IMpower110 trial; Non-small cell lung cancer; PD-L1 expression; Pembrolizumab.

PubMed Disclaimer

Conflict of interest statement

ML-B received speaker or consulting fees from Roche, Merck, BMS, AstraZeneca, Lilly, Pfizer and Takeda. DI received consulting fees or honorarium from MSD, Roche, Astrazeneca, Amgen, Pfizer, Sanofi, Bayer, BMS, GSK, Janssen, Takeda and BI, and received payments for lectures including service on speakers bureaus from Amgen Atrazeneca, Bayer, BMS, Roche, MSD, Pfizer and Takeda. RB-C received grants from Roche, consulting fees or honorarium from Roche, MSD, Astra, Bristol, support for travel to meetings for the study, manuscript preparation or other purposes Roche, MSD, Astra, Bristol, Pfizer and fees for participation in review activities such as data monitoring boards from Janssen. ME has not any conflicts of interest to declare. NA and DP are employees of Roche. DC is employee of Hygeia Consulting which received funding from Roche to conduct the analysis.

Figures

Fig. 1
Fig. 1
Model structure and transitions. PFS progression-free survival, PPS post-progression state
Fig. 2
Fig. 2
Tornado diagrama. ICUR incremental cost-utility ratio, QALY Quality-Adjusted Life Years, Admin administration, PFS progression-free, PPS post-progression state, A adverse events. aICER values in a are shown as negative because they correspond to the ratio of more QALYs at lower cost (dominant), ICER values in b correspond to the third quadrant, less QALYs with less cost
Fig. 3
Fig. 3
PSA results. Incremental cost-effectiveness plane. The deterministic results of the base case are shown with a dark filled dot. QALY quality-adjusted life year
See this image and copyright information in PMC

References

    1. GLOBOCAN. 2020 Global cancer observatory. https://gco.iarc.fr/
    1. Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016 a systematic analysis for the global burden of disease study global burden o. JAMA Oncol. 2018;4(11):1553–1568. doi: 10.1001/jamaoncol.2018.2706. - DOI - PMC - PubMed
    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi: 10.1002/ijc.29210. - DOI - PubMed
    1. SEOM. 2020 Sociedad española de oncologia médica. Cifras del cancer en españa 2020. 2020. 36 p.
    1. Reck M, Rabe KF. Precision diagnosis and treatment for advanced non–small-cell lung cancer. N Engl J Med. 2017;377(9):849–861. doi: 10.1056/NEJMra1703413. - DOI - PubMed